These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28550249)

  • 21. 5-HT6 receptor blockade differentially affects scopolamine-induced deficits of working memory, recognition memory and aversive learning in mice.
    Da Silva Costa-Aze V; Quiedeville A; Boulouard M; Dauphin F
    Psychopharmacology (Berl); 2012 Jul; 222(1):99-115. PubMed ID: 22367167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-HT6 receptor antagonists as potential therapeutics for cognitive impairment.
    Rossé G; Schaffhauser H
    Curr Top Med Chem; 2010; 10(2):207-21. PubMed ID: 20166958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotonin 6 receptor controls Alzheimer's disease and depression.
    Yun HM; Park KR; Kim EC; Kim S; Hong JT
    Oncotarget; 2015 Sep; 6(29):26716-28. PubMed ID: 26449188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of the 5-HT6 receptor antagonists Ro04-6790 and Ro65-7199 on latent inhibition and prepulse inhibition in the rat: comparison to clozapine.
    Leng A; Ouagazzal A; Feldon J; Higgins GA
    Pharmacol Biochem Behav; 2003 May; 75(2):281-8. PubMed ID: 12873617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective 5-HT6 receptor blockade improves spatial recognition memory and reverses age-related deficits in spatial recognition memory in the mouse.
    Da Silva Costa V; Duchatelle P; Boulouard M; Dauphin F
    Neuropsychopharmacology; 2009 Jan; 34(2):488-500. PubMed ID: 18596685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats.
    Arnt J; Bang-Andersen B; Grayson B; Bymaster FP; Cohen MP; DeLapp NW; Giethlen B; Kreilgaard M; McKinzie DL; Neill JC; Nelson DL; Nielsen SM; Poulsen MN; Schaus JM; Witten LM
    Int J Neuropsychopharmacol; 2010 Sep; 13(8):1021-33. PubMed ID: 20569520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone.
    Horisawa T; Ishibashi T; Nishikawa H; Enomoto T; Toma S; Ishiyama T; Taiji M
    Behav Brain Res; 2011 Jun; 220(1):83-90. PubMed ID: 21277905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466.
    Schechter LE; Lin Q; Smith DL; Zhang G; Shan Q; Platt B; Brandt MR; Dawson LA; Cole D; Bernotas R; Robichaud A; Rosenzweig-Lipson S; Beyer CE
    Neuropsychopharmacology; 2008 May; 33(6):1323-35. PubMed ID: 17625499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-HT6 receptor antagonists as treatment for age-related cognitive decline.
    Quiedeville A; Boulouard M; Da Silva Costa-Aze V; Dauphin F; Bouet V; Freret T
    Rev Neurosci; 2014; 25(3):417-27. PubMed ID: 24622786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
    Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M
    J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serotonin 5-HT6 receptor antagonists for the treatment of Alzheimer's disease.
    Geldenhuys WJ; Van der Schyf CJ
    Curr Top Med Chem; 2008; 8(12):1035-48. PubMed ID: 18691131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serotonin 5-HT
    Ferrero H; Solas M; Francis PT; Ramirez MJ
    CNS Drugs; 2017 Jan; 31(1):19-32. PubMed ID: 27914038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ADN-1184, a monoaminergic ligand with 5-HT6/7 receptor antagonist action, exhibits activity in animal models of anxiety.
    Partyka A; Wasik A; Jastrzębska-Więsek M; Mierzejewski P; Bieńkowski P; Kołaczkowski M; Wesołowska A
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):593-602. PubMed ID: 26979176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and synthesis of novel N-sulfonyl-2-indoles that behave as 5-HT
    Saavedra OM; Karila D; Brossard D; Rojas A; Dupuis D; Gohier A; Mannoury la Cour C; Millan MJ; Ortuno JC; Hanessian S
    Bioorg Med Chem; 2017 Jan; 25(1):38-52. PubMed ID: 28029458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological evaluation of the anxiolytic-like effects of EMD 386088, a partial 5-HT6 receptor agonist, in the rat elevated plus-maze and Vogel conflict tests.
    Jastrzębska-Więsek M; Siwek A; Partyka A; Kubacka M; Mogilski S; Wasik A; Kołaczkowski M; Wesołowska A
    Neuropharmacology; 2014 Oct; 85():253-62. PubMed ID: 24905144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist.
    Ring RH; Schechter LE; Leonard SK; Dwyer JM; Platt BJ; Graf R; Grauer S; Pulicicchio C; Resnick L; Rahman Z; Sukoff Rizzo SJ; Luo B; Beyer CE; Logue SF; Marquis KL; Hughes ZA; Rosenzweig-Lipson S
    Neuropharmacology; 2010 Jan; 58(1):69-77. PubMed ID: 19615387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs.
    Millan MJ; Dekeyne A; Gobert A; Brocco M; Mannoury la Cour C; Ortuno JC; Watson D; Fone KCF
    Neuropharmacology; 2020 Oct; 177():108099. PubMed ID: 32525060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dimebolin is a 5-HT6 antagonist with acute cognition enhancing activities.
    Schaffhauser H; Mathiasen JR; Dicamillo A; Huffman MJ; Lu LD; McKenna BA; Qian J; Marino MJ
    Biochem Pharmacol; 2009 Oct; 78(8):1035-42. PubMed ID: 19549510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders.
    Nirogi R; Jayarajan P; Shinde A; Mohammed AR; Grandhi VR; Benade V; Goyal VK; Abraham R; Jasti V; Cummings J
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.